The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry

Autor: Panagiotis Diamantopoulos, Dafni Koumbi, Ioannis Kotsianidis, Vasiliki Pappa, Argiris Symeonidis, Athanasios Galanopoulos, Panagiotis Zikos, Helen A. Papadaki, Panayiotis Panayiotidis, Maria Dimou, Eleftheria Hatzimichael, George Vassilopoulos, Susan Delimpasis, Despoina Mparmparousi, Sotirios Papageorgiou, Eleni Variami, Marie‐Christine Kyrtsonis, Aekaterini Megalakaki, Maria Kotsopoulou, Panagiotis Repousis, Ioannis Adamopoulos, Flora Kontopidou, Dimitrios Christoulas, Alexandra Kourakli, Dimitrios Tsokanas, Menelaos Konstantinos Papoutselis, Georgios Kyriakakis, Nora‐Athina Viniou, the Hellenic MDS study group

Publikováno v: Cancer Medicine, Vol 8, Iss 5, Pp 2056-2063 (2019)

Abstract In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in th

Externí odkaz: https://doaj.org/article/1ac96392361c45e28bc216058adc8d5a

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry

Autor: Diamantopoulos, P. Koumbi, D. Kotsianidis, I. Pappa, V. Symeonidis, A. Galanopoulos, A. Zikos, P. Papadaki, H.A. Panayiotidis, P. Dimou, M. Hatzimichael, E. Vassilopoulos, G. Delimpasis, S. Mparmparousi, D. Papageorgiou, S. Variami, E. Kyrtsonis, M.-C. Megalakaki, A. Kotsopoulou, M. Repousis, P. Adamopoulos, I. Kontopidou, F. Christoulas, D. Kourakli, A. Tsokanas, D. Konstantinos Papoutselis, M. Kyriakakis, G. Viniou, N.-A. the Hellenic MDS study group

In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ce5198a9deb75623d6bd5a5afc708c09
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078566

The Stat3/5 signaling biosignature in hematopoietic stem/progenitor cells predicts response and outcome in myelodysplastic syndrome patients treated with azacitidine

Autor: Miltiades, P. Lamprianidou, E. Vassilakopoulos, T.P. Papageorgiou, S.G. Galanopoulos, A.G. Kontos, C.K. Adamopoulos, P.G. Nakou, E. Vakalopoulou, S. Garypidou, V. Papaioannou, M. Hatjiharissi, E. Papadaki, H.A. Spanoudakis, E. Pappa, V. Scorilas, A. Tsatalas, C. Kotsianidis, I. on behalf of the Hellenic MDS Study Group

Purpose: Azacitidine is the mainstay of high-risk myelodysplastic syndromes (MDS) therapy, but molecular predictors of response and the mechanisms of resistance to azacitidine remain largely unidentified. Deregulation of signaling via Stat3 and Stat5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::accf574a43536f5dd91aa9580c657e10
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086426

Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.

Autor: Mpakou V; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Spathis A; Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Bouchla A; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Tsakiraki Z; Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Kontsioti F; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Papageorgiou S; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Bazani E; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Gkontopoulos K; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Thomopoulos T; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Glezou I; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Galanopoulos A; Department of Clinical Hematology, G. Gennimatas District General Hospital, Athens, Greece.; The Hellenic MDS Study Group, Hellenic Society of Haematology, Athens, Greece., Symeonidis A; The Hellenic MDS Study Group, Hellenic Society of Haematology, Athens, Greece.; Hematology Division, Dept of Int. Medicine, University of Patras Medical School, Patras, Greece., Diamantopoulos PT; First Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Viniou NA; The Hellenic MDS Study Group, Hellenic Society of Haematology, Athens, Greece.; First Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Kontandreopoulou CN; First Department of Internal Medicine, Hematology Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Zafeiropoulou K; Hematology Division, Dept of Int. Medicine, University of Patras Medical School, Patras, Greece., Kotsianidis I; The Hellenic MDS Study Group, Hellenic Society of Haematology, Athens, Greece.; Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece., Lamprianidou E; Department of Hematology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece., Foukas P; Second Department of Pathology, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Mpamias A; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece., Pappa V; Second Department of Internal Medicine and Research Institute, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece.; The Hellenic MDS Study Group, Hellenic Society of Haematology, Athens, Greece.

Publikováno v: Hematological oncology [Hematol Oncol] 2021 Apr; Vol. 39 (2), pp. 231-242. Date of Electronic Publication: 2021 Jan 01.